Abstract
Bortezomib induces clinical remission and reduction of <scp>ADAMTS</scp>13 inhibitory antibodies in relapsed refractory idiopathic thrombotic thrombocytopenic purpura
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have